- Patent Title: Composition for promoting chondrocyte differentiation or treating cartilage diseases, containing KLF10 expression inhibitor, and method for promoting cartilage differentiation by using same
-
Application No.: US15108525Application Date: 2014-12-30
-
Publication No.: US09963744B2Publication Date: 2018-05-08
- Inventor: Gun-Il Im , Jong-Min Lee
- Applicant: DONGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION , KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE (KHIDI)
- Applicant Address: KR Seoul
- Assignee: DONGGUK UNIVERSITY INDUSTRY—ACADEMIC COOPERATION FOUNDATION
- Current Assignee: DONGGUK UNIVERSITY INDUSTRY—ACADEMIC COOPERATION FOUNDATION
- Current Assignee Address: KR Seoul
- Agency: Lucas & Mercanti, LLP
- Priority: KR10-2013-0168736 20131231; KR10-2014-0191592 20141229
- International Application: PCT/KR2014/013006 WO 20141230
- International Announcement: WO2015/102351 WO 20150709
- Main IPC: A61K31/70
- IPC: A61K31/70 ; C07H21/02 ; C07H21/04 ; C12Q1/68 ; C12N5/077 ; C12N15/113 ; C12N5/00

Abstract:
The present invention relates to a Krueppel-like factor 10 (KLF10) gene expression inhibitor promoting cartilage differentiation, and more specifically, to: a composition for promoting chondrocyte differentiation or treating cartilage diseases, containing a KLF10 gene expression inhibitor promoting cartilage differentiation and inhibiting the hypertrophy and dedifferentiation of chondrocytes; a cell therapeutic agent containing the composition; a method for promoting cartilage differentiation in bone marrow stem cells, comprising a step of expressing the composition in bone marrow stem cells; and a method for screening a chondrocyte differentiation promoter or a chondrocyte therapeutic agent. The present invention first examined the generation inhibition mechanism of indian hedgehog (IHH) protein of which the molecular biological mechanism has not yet been clearly examined, and ascertained that chondrocyte differentiation is promoted and chondrocyte hypertrophy is inhibited when chondrocyte differentiation is induced by expressing the KLF10 expression inhibitor in bone marrow stem cells. Therefore, the present invention has an advantage of enabling the use of bone marrow stem cells, which express a KLF10 expression inhibitor, as a chondrocyte therapeutic agent.
Public/Granted literature
Information query